← Back to Search

Nonsteroidal Anti-inflammatory Drug

Pilot PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity (PARTUM Trial)

Phase < 1
Waitlist Available
Led By Leslie Skeith, MD
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months

Summary

This trial is testing whether aspirin can prevent blood clots in pregnant women.

Eligible Conditions
  • Deep Vein Thrombosis (DVT)
  • Deep Vein Thrombosis
  • Aspirin
  • Postpartum

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Recruitment Rate
Secondary study objectives
Bleeding Event Rate
Consent Rate
Study Drug Compliance
+3 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: AspirinActive Control1 Intervention
Aspirin 81 mg daily for six weeks post-randomization (postpartum)
Group II: PlaceboPlacebo Group1 Intervention
Placebo daily for six weeks post-randomization (postpartum)

Find a Location

Who is running the clinical trial?

University of CalgaryLead Sponsor
811 Previous Clinical Trials
889,319 Total Patients Enrolled
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,394 Previous Clinical Trials
26,527,601 Total Patients Enrolled
6 Trials studying Deep Vein Thrombosis
2,920 Patients Enrolled for Deep Vein Thrombosis
Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) NetworkNETWORK
11 Previous Clinical Trials
17,226 Total Patients Enrolled
Leslie Skeith, MDPrincipal InvestigatorUniversity of Calgary
3 Previous Clinical Trials
9,631 Total Patients Enrolled
Marc Rodger, MDPrincipal InvestigatorMcGill University Health Centre/Research Institute of the McGill University Health Centre
4 Previous Clinical Trials
9,202 Total Patients Enrolled
2 Trials studying Deep Vein Thrombosis
396 Patients Enrolled for Deep Vein Thrombosis

Media Library

Aspirin 81 mg (Nonsteroidal Anti-inflammatory Drug) Clinical Trial Eligibility Overview. Trial Name: NCT04153760 — Phase < 1
Deep Vein Thrombosis Research Study Groups: Aspirin, Placebo
Deep Vein Thrombosis Clinical Trial 2023: Aspirin 81 mg Highlights & Side Effects. Trial Name: NCT04153760 — Phase < 1
Aspirin 81 mg (Nonsteroidal Anti-inflammatory Drug) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04153760 — Phase < 1
~49 spots leftby Jan 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top